Bryce Jw van Denderen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bryce Jw van Denderen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Boris Sarcevic
A Cell Cycle and Cancer Unit , St Vincent's Medical Institute , Melbourne , Australia
1 shared publication - Bruce E. Kemp
St. Vincent's Institute of Medical Research and Department of Medicine, University of Melbourne & Mary MacKillop Institute for Health Research, Australian Catholic University Fitzroy, Fitzroy, Victoria, Australia
1 shared publication - Cletus A. Pinto
Invasion and Metastasis Unit, St Vincent’s Institute, 9 Princes St, Fitzroy 3065, Victoria, Australia
1 shared publication - Donald F. Newgreen
Murdoch Children's Research Institute, Royal Children's Hospital, Parkville 3052, Victoria, Australia
1 shared publication - Eliza Tl Soo
Invasion and Metastasis Unit, St Vincent’s Institute, 9 Princes St, Fitzroy 3065, Victoria, Australia
1 shared publication - Erik Walter Thompson
Centre for Genomics and Personalised Health and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia
1 shared publication
Latest Publications
- Open Access
- 27 November 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (6) , R113
Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells
Introduction: Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears to be required for restoration of proliferation in secondary tumors. We studied the interplay between EMT and proliferation control by MYB in breast cancer cells. Methods: MYB, ZEB1, and CDH1 expression levels were manipulated by lentiviral small-hairpin RNA (shRNA)-mediated knockdown/overexpression, and verified with Western blotting, immunocytochemistry, and qRT-PCR. Proliferation was assessed with bromodeoxyuridine pulse labeling and flow cytometry, and sulforhodamine B assays. EMT was induced with epidermal growth factor for 9 days or by exposure to hypoxia (1% oxygen) for up to 5 days, and assessed with qRT-PCR, cell morphology, and colony morphology. Protein expression in human breast cancers was assessed with immunohistochemistry. ZEB1-MYB promoter binding and repression were determined with Chromatin Immunoprecipitation Assay and a luciferase reporter assay, respectively. Student paired t tests, Mann–Whitney, and repeated measures two-way ANOVA tests determined statistical significance (P < 0.05). Results: Parental PMC42-ET cells displayed higher expression of ZEB1 and lower expression of MYB than did the PMC42-LA epithelial variant. Knockdown of ZEB1 in PMC42-ET and MDA-MB-231 cells caused increased expression of MYB and a transition to a more epithelial phenotype, which in PMC42-ET cells was coupled with increased proliferation. Indeed, we observed an inverse relation between MYB and ZEB1 expression in two in vitro EMT cell models, in matched human breast tumors and lymph node metastases, and in human breast cancer cell lines. Knockdown of MYB in PMC42-LA cells (MYBsh-LA) led to morphologic changes and protein expression consistent with an EMT. ZEB1 expression was raised in MYBsh-LA cells and significantly repressed in MYB-overexpressing MDA-MB-231 cells, which also showed reduced random migration and a shift from mesenchymal to epithelial colony morphology in two dimensional monolayer cultures. Finally, we detected binding of ZEB1 to MYB promoter in PMC42-ET cells, and ZEB1 overexpression repressed MYB promoter activity. Conclusions: This work identifies ZEB1 as a transcriptional repressor of MYB and suggests a reciprocal MYB-ZEB1 repressive relation, providing a mechanism through which proliferation and the epithelial phenotype may be coordinately modulated in breast cancer cells.
- 27 November 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (6) , R113
Open AccessDirect repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells
Introduction: Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears to be required for restoration of proliferation in secondary tumors. We studied the interplay between EMT and proliferation control by MYB in breast cancer cells. Methods: MYB, ZEB1, and CDH1 expression levels were manipulated by lentiviral small-hairpin RNA (shRNA)-mediated knockdown/overexpression, and verified with Western blotting, immunocytochemistry, and qRT-PCR. Proliferation was assessed with bromodeoxyuridine pulse labeling and flow cytometry, and sulforhodamine B assays. EMT was induced with epidermal growth factor for 9 days or by exposure to hypoxia (1% oxygen) for up to 5 days, and assessed with qRT-PCR, cell morphology, and colony morphology. Protein expression in human breast cancers was assessed with immunohistochemistry. ZEB1-MYB promoter binding and repression were determined with Chromatin Immunoprecipitation Assay and a luciferase reporter assay, respectively. Student paired t tests, Mann–Whitney, and repeated measures two-way ANOVA tests determined statistical significance (P < 0.05). Results: Parental PMC42-ET cells displayed higher expression of ZEB1 and lower expression of MYB than did the PMC42-LA epithelial variant. Knockdown of ZEB1 in PMC42-ET and MDA-MB-231 cells caused increased expression of MYB and a transition to a more epithelial phenotype, which in PMC42-ET cells was coupled with increased proliferation. Indeed, we observed an inverse relation between MYB and ZEB1 expression in two in vitro EMT cell models, in matched human breast tumors and lymph node metastases, and in human breast cancer cell lines. Knockdown of MYB in PMC42-LA cells (MYBsh-LA) led to morphologic changes and protein expression consistent with an EMT. ZEB1 expression was raised in MYBsh-LA cells and significantly repressed in MYB-overexpressing MDA-MB-231 cells, which also showed reduced random migration and a shift from mesenchymal to epithelial colony morphology in two dimensional monolayer cultures. Finally, we detected binding of ZEB1 to MYB promoter in PMC42-ET cells, and ZEB1 overexpression repressed MYB promoter activity. Conclusions: This work identifies ZEB1 as a transcriptional repressor of MYB and suggests a reciprocal MYB-ZEB1 repressive relation, providing a mechanism through which proliferation and the epithelial phenotype may be coordinately modulated in breast cancer cells.
- Open Access
- 1 September 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (1) , 275-285
Germline deletion of AMP‐activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function
Since AMP‐activated protein kinase (AMPK) plays important roles in modulating metabolism in response to diet and exercise, both of which influence bone mass, we examined the influence of AMPK on bone mass in mice. AMPK is an αβy hetero‐trimer where the β subunit anchors the a catalytic and y regulatory subunits. Germline deletion of either AMPK β 1orβ2 subunit isoforms resulted in reduced trabecular bone density and mass, but without effects on osteoclast (OC) or osteoblast (OB) numbers, as compared to wild‐type littermate controls. We tested whether activating AMPK in vivo would enhance bone density but found AICA‐riboside treatment caused a profound loss of trabecular bone volume (49.5%) and density and associated increased OC numbers. Consis‐tent with this, AICA‐riboside strongly stimulated OC differentiation in vitro, in an adenosine kinase‐depen‐dent manner. OCs and macrophages (unlike OBs) lacked AMPK β2 subunit expression, and when generated from AMPK β1 _/_ mice displayed no detectable AMPK activity. Nevertheless, AICA‐riboside was equally effective at stimulating OC differentiation from wildtype or β1 _/_ progenitors, indicating that AMPK is not essential for OC differentiation or the stimulatory action of AICA‐riboside. These results show that AMPK is required to maintain normal bone density, but not through bone cell differentiation, and does not mediate powerful osteolytic effects of AICA‐riboside.—Quinn, J. M. W., Tam, S., Sims, N. A., Saleh, H., McGregor, N. E., Poulton, I. J., Scott, J. W., Gillespie, M. T., Kemp, B. E., van Denderen, B. J. W. Germline deletion of AMP‐activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J . 24, 275–285 (2010). www.fasebj.org
- 1 September 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (1) , 275-285
Open AccessGermline deletion of AMP‐activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function
Since AMP‐activated protein kinase (AMPK) plays important roles in modulating metabolism in response to diet and exercise, both of which influence bone mass, we examined the influence of AMPK on bone mass in mice. AMPK is an αβy hetero‐trimer where the β subunit anchors the a catalytic and y regulatory subunits. Germline deletion of either AMPK β 1orβ2 subunit isoforms resulted in reduced trabecular bone density and mass, but without effects on osteoclast (OC) or osteoblast (OB) numbers, as compared to wild‐type littermate controls. We tested whether activating AMPK in vivo would enhance bone density but found AICA‐riboside treatment caused a profound loss of trabecular bone volume (49.5%) and density and associated increased OC numbers. Consis‐tent with this, AICA‐riboside strongly stimulated OC differentiation in vitro, in an adenosine kinase‐depen‐dent manner. OCs and macrophages (unlike OBs) lacked AMPK β2 subunit expression, and when generated from AMPK β1 _/_ mice displayed no detectable AMPK activity. Nevertheless, AICA‐riboside was equally effective at stimulating OC differentiation from wildtype or β1 _/_ progenitors, indicating that AMPK is not essential for OC differentiation or the stimulatory action of AICA‐riboside. These results show that AMPK is required to maintain normal bone density, but not through bone cell differentiation, and does not mediate powerful osteolytic effects of AICA‐riboside.—Quinn, J. M. W., Tam, S., Sims, N. A., Saleh, H., McGregor, N. E., Poulton, I. J., Scott, J. W., Gillespie, M. T., Kemp, B. E., van Denderen, B. J. W. Germline deletion of AMP‐activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J . 24, 275–285 (2010). www.fasebj.org